I am a Principal Investigator with expertise in RNA-based drug discovery and neuroimmune interactions, particularly in neuroinflammatory conditions. At Heidelberg University, I led research that uncovered key insights into RNA-mediated neuroimmune mechanisms in atopic dermatitis and axonal RNA transport in pain, paving the way for innovative therapeutic approaches. My experience includes managing interdisciplinary teams and securing prestigious grants, such as the Type 2 Innovation Grant from Sanofi-Genzyme. Through my work with the European Pain Federation (EFIC), I have translated scientific advancements into EU-funded projects, benefiting patients directly.As an editorial board member for Genomic Data and Brain Sciences, and a reviewer for over 65 scientific journals, I have developed strong critical analysis skills and gained a broad perspective on cutting-edge biomedical research. These roles enhance my ability to assess scientific innovations, informing my vision for developing a startup.I hold a Ph.D. in Pharmacology from Heidelberg University, along with advanced certifications in drug discovery, project management, and leadership, providing me with a comprehensive approach to research and drug development. My work has attracted significant funding, including the Type 2 Innovation Grant from Sanofi-Genzyme, and I have received awards like the Max von Frey Award and the Excellence Fellowship from Heidelberg University.With over 25 peer-reviewed publications and an h-index of 21, I have made substantial contributions to the scientific community, with studies published in leading journals like PAIN and EMBO Molecular Medicine. My patent application for selective inhibitors for neuropathic pain further demonstrates my commitment to innovative research.Currently, I am focusing on a stealth-mode startup dedicated to developing novel RNA-based drugs for complex diseases. This venture aims to translate nearly two decades of research into practical treatments. I seek collaborations and investors who share my vision for leveraging RNA technology to create transformative healthcare solutions.Let’s connect to explore potential partnerships to bring these breakthrough therapies to market.